The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

XDS

Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463

Refinement of Macromolecular Structures by the Maximum-Likelihood Method

Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796

MOLREP : an Automated Program for Molecular Replacement

Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,756

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML

Ewald, L., Dittmann, J., Vogler, M., & Fulda, S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2156-2 · Cited by 42

SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication

Pan, P., Ge, W., Lei, Z., Luo, W. P., Liu, Y., Guan, Z., Chen, L., Yu, Z., Shen, M., Hu, D., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01459-8 · Cited by 41

The Regulation of Tumor Cell Invasion and Metastasis by Endoplasmic Reticulum-to-Mitochondrial Ca2+ Transfer

White, C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00171 · Cited by 42

Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer

Li, H., Liu, L., Chang, H., Zou, Z., & Xing, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0169-2 · Cited by 43

Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins

Kump, K. J., Miao, L., Mady, A. S. A., Ansari, N. H., Shrestha, U. K., Yang, Y., Pal, M., Liao, C., Perdih, A., Abulwerdi, F. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01442 · Cited by 41

Gossypol inhibits cullin neddylation by targeting SAG-CUL5 and RBX1-CUL1 complexes

Yu, Q., Hu, Z., Shen, Y., Jiang, Y., Pan, P., Hou, T., Pan, Z., Huang, J., & Sun, Y. (2020) · Neoplasia · doi:10.1016/j.neo.2020.02.003 · Cited by 41

A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma

Bierbrauer, A., Jacob, M., Vogler, M., & Fulda, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0795-9 · Cited by 41

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Tannan, N. B., Manzari, M. T., Herviou, L., Ferreira, M. D. S., Hagen, C. J., Kiguchi, H., Manova-Todorova, K. O., Seshan, V., de Stanchina, E., Heller, D. A., et al. (2020) · Blood · doi:10.1182/blood.2020008017 · Cited by 41

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

Scherr, A., Möck, A., Gdynia, G., Schmitt, N., Heilig, C. E., Korell, F., Rhadakrishnan, P., Hoffmeister‐Wittmann, P., Metzeler, K. H., Schulze‐Osthoff, K., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03092-7 · Cited by 41

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

Al‐Odat, O. S., Suskil, M. V., Chitren, R. J., Elbezanti, W. O., Srivastava, S. K., Budak-Alpdoǧan, T., Jonnalagadda, S. C., Aggarwal, B. B., & Pandey, M. K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.699629 · Cited by 42

Dynamic reconfiguration of pro‐apoptotic BAK on membranes

Sandow, J. J., Tan, I. K. L., Huang, A. S., Masaldan, S., Bernardini, J. P., Wardak, A. Z., Birkinshaw, R. W., Ninnis, R. L., Liu, Z., Dalseno, D., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020107237 · Cited by 41

Chlamydia trachomatis inhibits apoptosis in infected cells by targeting the pro-apoptotic proteins Bax and Bak

Kontchou, C. W., Gentle, I. E., Weber, A., Schoeniger, A., Edlich, F., & Häcker, G. A. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00995-0 · Cited by 40

Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice

Arandjelovic, P., Kim, Y., Cooney, J. P., Preston, S., Doerflinger, M., McMahon, J. H., Garner, S. E., Zerbato, J. M., Roche, M., Tumpach, C., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101178 · Cited by 41

BCL-2 inhibition in haematological malignancies: Clinical application and complications

Fowler-Shorten, D. J., Hellmich, C., Markham, M., Bowles, K. M., & Rushworth, S. A. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101195 · Cited by 41

Infection with flaviviruses requires BCLXL for cell survival

Suzuki, T., Okamoto, T., Katoh, H., Sugiyama, Y., Kusakabe, S., Tokunaga, M., Hirano, J., Miyata, Y., Fukuhara, T., Ikawa, M., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007299 · Cited by 40

Genome Instability in Multiple Myeloma: Facts and Factors

Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 43

Targeting Apoptosis to Overcome Chemotherapy Resistance

Doğan, E., Kara, H. G., Kosova, B., & Çetintaş, V. B. (2021) · Exon Publications eBooks · doi:10.36255/exon-publications.metastasis.chemotherapy-resistance · Cited by 39

Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer

Cao, F., Gong, Y., Kang, X., Lu, Z., Wang, Y., Zhao, K., Miao, Z., Liao, M., & Xu, Z. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114662 · Cited by 39

Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia

Li, X., Zhou, J., Wen, X., Zhang, T., Wu, D., Deng, Z., Zhang, Z., Lian, X., He, P.-F., Yao, X., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194549 · Cited by 40

The Incomplete Puzzle of the BCL2 Proteins

Flores-Romero, H., & García-Sáez, A. J. (2019) · Cells · doi:10.3390/cells8101176 · Cited by 38

The Clinicopathological and Molecular Characteristics of Endocervical Gastric-Type Adenocarcinoma and the Use of Claudin18.2 as a Potential Therapeutic Target

Yang, J., Yang, P., Ding, Y. F., Liu, Y., Wang, Y., Liu, Y., & Liu, C. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100569 · Cited by 38

The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer

Alexandrou, S., George, S. M., Ormandy, C. J., Lim, E., Oakes, S. R., & Caldon, C. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030667 · Cited by 42

Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism

Castelli, G., Pelosi, E., & Testa, U. (2019) · Cancers · doi:10.3390/cancers11020260 · Cited by 39

Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells

Teh, C. E., Gong, J., Segal, D., Tan, T., Vandenberg, C. J., Fedele, P. L., Low, M. S. Y., Grigoriadis, G., Harrison, S. J., Strasser, A., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0498-z · Cited by 38

Targeted Apoptosis of Ductular Reactive Cells Reduces Hepatic Fibrosis in a Mouse Model of Cholestasis

Azad, A. I., Krishnan, A., Troop, L., Li, Y., Katsumi, T., Pavelko, K. D., Kostallari, E., Guicciardi, M. E., & Gores, G. J. (2020) · Hepatology · doi:10.1002/hep.31211 · Cited by 38

Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy

Mittal, P., Singh, S., Sinha, R., Shrivastava, A., Singh, A. K., & Singh, I. K. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.07.166 · Cited by 39

Personalized treatment based on mini patient‐derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma

Zhao, P., Chen, H., Wen, D., Mou, S., Zhang, F., & Zheng, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0323-y · Cited by 37

Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis

Folkerts, H., Wierenga, A. T. J., van den Heuvel, F. A. J., Woldhuis, R. R., Kluit, D. S., Jaques, J., Schuringa, J. J., & Vellenga, E. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1648-4 · Cited by 41

Cell death in cancer

Conrad, M., Strasser, A., Jost, P. J., Yuan, J., Shao, F., Vandenabeele, P., & Wahida, A. (2026) · Cell · doi:10.1016/j.cell.2026.03.024 · Cited by 40

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance

Klümper, T., Bruckmueller, H., Diewock, T., Kaehler, M., Haenisch, S., Pott, C., Bruhn, O., & Cascorbi, I. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00183-1 · Cited by 36

Targeting Bcl-2 Family Proteins: What, Where, When?

Senichkin, V. V., Pervushin, N. V., Zuev, A. P., Zhivotovsky, B., & Kopeina, G. S. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920100090 · Cited by 37

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer

Doffo, J., Bamopoulos, S. A., Köse, H., Orben, F., Zang, C., Pons, M., den Dekker, A. T., Brouwer, R. W. W., Baluapuri, A., Habringer, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105691119 · Cited by 36

New Approaches to Difficult Drug Targets: The Phosphatase Story

Lazo, J. S., McQueeney, K. E., & Sharlow, E. R. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217721142 · Cited by 38

Coexisting genomic aberrations associated with lymph node metastasis in breast cancer

Bao, L., Qian, Z., Lyng, M., Wang, L., Yu, Y., Wang, T., Zhang, X., Yang, H., Brünner, N., Wang, J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97449 · Cited by 35

Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1

Ow, T. J., Fulcher, C. D., Thomas, C., Broin, P. Ó., López, A., Reyna, D. E., Smith, R. V., Sarta, C., Prystowsky, M. B., Schlecht, N. F., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26563 · Cited by 35

Discovery of β-carboline copper(II) complexes as Mcl-1 inhibitor and in vitro and in vivo activity in cancer models

Lü, X., Liu, Y.-C., Orvig, C., Liang, H., & Chen, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111567 · Cited by 35

Bile acid-induced “Minority MOMP” promotes esophageal carcinogenesis while maintaining apoptotic resistance via Mcl-1

Xu, Y., Surman, D. R., Diggs, L. P., Xi, S., Gao, S., Gurusamy, D., McLoughlin, K. C., Drake, J. A., Feingold, P. L., Brown, K., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1029-6 · Cited by 35

Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review)

Yuan, J., Lan, H., Jiang, X., Zeng, D. X., & Xiao, S. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4689 · Cited by 36

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma

Arulananda, S., O’Brien, M., Evangelista, M., Jenkins, L. J., Poh, A. R., Walkiewicz, M., Leong, T. Y.-M., Mariadason, J. M., Cebon, J. S., Balachander, S. B., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00505-0 · Cited by 35

Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

Zañudo, J. G. T., Mao, P., Alcon, C., Kowalski, K. J., Johnson, G. N., Xu, G., Baselga, J. M., Scaltriti, M., Letai, A. G., Montero, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1208 · Cited by 37

Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers

Rago, F., DiMare, M. T., Elliott, G., Ruddy, D. A., Sovath, S., Kerr, G., Bhang, H. C., & Jagani, Z. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.09.009 · Cited by 35

The chemical biology of apoptosis: Revisited after 17 years

Yang, S., Mao, Y., Zhang, H., Xu, Y., An, J., & Huang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.019 · Cited by 35

Site-Dependent Cysteine Lipidation Potentiates the Activation of Proapoptotic BAX

Cohen, D. T., Wales, T. E., McHenry, M. W., Engen, J. R., & Walensky, L. D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.057 · Cited by 34

MCL-1 is a clinically targetable vulnerability in breast cancer

Winder, M. L., & Campbell, K. J. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2054096 · Cited by 35

USP13: Multiple Functions and Target Inhibition

Li, X., Yang, G. H., Zhang, W., Qin, B., Ye, Z., Shi, H., Zhao, X., Chen, Y., Song, B., Mei, Z., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.875124 · Cited by 34

Chaperone-mediated autophagy promotes lung cancer cell survival through selective stabilization of the pro-survival protein, MCL1

Suzuki, J., Nakajima, W., Suzuki, H., Asano, Y., & Tanaka, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.037 · Cited by 35

DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis

Milani, M., Byrne, D. P., Greaves, G., Butterworth, M., Cohen, G. M., Eyers, P. A., & Varadarajan, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.485 · Cited by 33

Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A

Samra, A. A., Robert, A., Gov, C., Favre, L., Eloy, L., Jacquet, E., Bignon, J. S., Wiels, J., Desrat, S., & Roussi, F. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.100 · Cited by 33

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

Mukherjee, N., Amato, C. M., Skees, J., Todd, K. J., Lambert, K. A., Robinson, W. A., Gulick, R. J. V., Weight, R. M., Dart, C. R., Tobin, R. P., et al. (2020) · Cancers · doi:10.3390/cancers12082182 · Cited by 35

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA

Weller, S., Toennießen, A., Schaefer, B., Beigl, T. B., Muenchow, A., Böpple, K., Hofmann, U., Gillissen, B., Aulitzky, W. E., Kopp, H., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01009-1 · Cited by 35

Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer

Wedam, R., Greer, Y. E., Wisniewski, D. J., Weltz, S., Kundu, M., Voeller, D. M., & Lipkowitz, S. (2023) · Cancers · doi:10.3390/cancers15071936 · Cited by 36

S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver

Letai, A. G. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.11.016 · Cited by 33

Phosphorylation alters Bim‐mediated Mcl‐1 stabilization and priming

Conage‐Pough, J. E., & Boise, L. H. (2018) · The FEBS Journal · doi:10.1111/febs.14505 · Cited by 32

Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia

Budhraja, A., Turnis, M. E., Churchman, M. L., Kothari, A., Yang, X., Xu, H., Kaminska, E. K., Panetta, J. C., Finkelstein, D., Mullighan, C. G., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1231 · Cited by 32

Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system

Bornschein, S., Demeyer, S., Stirparo, R., Gielen, O., Vicente, C., Geerdens, E., Ghesquière, B., Aerts, S., Cools, J., & de Bock, C. E. (2017) · Leukemia · doi:10.1038/leu.2017.328 · Cited by 34

Small-molecule PROTACs: Novel Agents for Cancer Therapy

Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 32

Genomics-guided pre-clinical development of cancer therapies

Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32

Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far

Elwakeel, A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.879632 · Cited by 32

Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies

Zarnegar‐Lumley, S., Caldwell, K. J., & Rubnitz, J. E. (2022) · Leukemia · doi:10.1038/s41375-022-01619-9 · Cited by 32

PTBP1 enhances miR-101-guided AGO2 targeting to MCL1 and promotes miR-101-induced apoptosis

Cui, J., & Placzek, W. J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0551-8 · Cited by 32

Tertiary Structural Motif Sequence Statistics Enable Facile Prediction and Design of Peptides that Bind Anti-apoptotic Bfl-1 and Mcl-1

Frappier, V., Jenson, J. M., Zhou, J., Grigoryan, G., & Keating, A. E. (2019) · Structure · doi:10.1016/j.str.2019.01.008 · Cited by 34

MCL1 Is Required for Maintenance of Intestinal Homeostasis and Prevention of Carcinogenesis in Mice

Healy, M. E., Boege, Y., Hodder, M. C., Böhm, F., Malehmir, M., Scherr, A., Jetzer, J., Chan, L. K., Parrotta, R., Jacobs, K., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.017 · Cited by 33

Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion

Young, A. I. J., Timpson, P., Gallego‐Ortega, D., Ormandy, C. J., & Oakes, S. R. (2017) · Cell Adhesion & Migration · doi:10.1080/19336918.2017.1393591 · Cited by 34

Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies

Tantawy, S. I., Sarkar, A. K., Hubner, S. E., Tan, Z., Wierda, W. G., Eldeib, A., Zhang, S., Kornblau, S. M., & Gandhi, V. V. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2088 · Cited by 31

Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future

Choi, J., Shukla, M., & Abdul‐Hay, M. (2023) · Acta Haematologica · doi:10.1159/000531628 · Cited by 34

Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions

Deng, H., Han, Y., Liu, L., Zhang, H., Liu, D., Wen, J., Huang, M., & Zhao, L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01998 · Cited by 31

Mitochondrial orchestration of PANoptosis: mechanisms, disease pathogenesis, and emerging therapeutic frontiers

Zhang, J., Fu, X., Jia, F., Yu, J., Zhang, J., Bai, A., Cui, M., Zhang, L., & Yao, K. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02750-z · Cited by 34

Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death

Domostegui, A., Peddigari, S., Mercer, C. A., Iannizzotto, F., Rodríguez, M. L., Garcia‐Cajide, M., Amador, V., Diepstraten, S. T., Kelly, G. L., Salazar, R., et al. (2021) · Blood · doi:10.1182/blood.2020007452 · Cited by 31

Discovery and in Vivo Evaluation of Macrocyclic Mcl‑1 Inhibitors Featuring an α‑Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere

Rescourio, G., González, A. Z., Jabri, S. Y., Belmontes, B., Moody, G. E., Whittington, D., Huang, X., Caenepeel, S. R., Cardozo, M. G., Cheng, A. C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01310 · Cited by 31

Development of venetoclax for therapy of lymphoid malignancies

Zhu, H., & Almasan, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s109325 · Cited by 31

Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck

Carter, R. J., Milani, M., Butterworth, M., Alotibi, A., Harper, N. W., Yedida, G., Greaves, G., Al-Zebeeby, A., Jorgensen, A., Schache, A. G., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2150-8 · Cited by 31

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Shen, Q., Li, J., Mai, J., Zhang, Z., Fisher, A., Wu, X., Li, Z., Ramirez, M., Chen, S., & Shen, H. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1040-9 · Cited by 30

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells

Grundy, M. A., Balakrishnan, S., Fox, M., Seedhouse, C., & Russell, N. H. (2018) · Oncotarget · doi:10.18632/oncotarget.26540 · Cited by 30

α7 nicotinic acetylcholine receptor upregulation by anti-apoptotic Bcl-2 proteins

Dawe, G. B., Yu, H. Y., Gu, S., Blackler, A. N., Matta, J. A., Siuda, E. R., Rex, E., & Bredt, D. S. (2019) · Nature Communications · doi:10.1038/s41467-019-10723-x · Cited by 30

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Boiko, S., Proia, T. A., Martin, M. S., Gregory, G. P., Wu, M. M., Aryal, N. K., Hattersley, M. M., Shao, W., Saeh, J. C., Fawell, S. E., et al. (2020) · Blood · doi:10.1182/blood.2020008528 · Cited by 30

New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy

Trisciuoglio, D., & Bufalo, D. D. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.027 · Cited by 30

ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins

Alcon, C., Zañudo, J. G. T., Albert, R., Wagle, N., Scaltriti, M., Letai, A. G., Samitier, J., & Montero, J. (2021) · Cells · doi:10.3390/cells10071659 · Cited by 32

Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells

Chen, R., Chen, Y., Xiong, P., Zheleva, D. I., Blake, D., Keating, M. J., Wierda, W. G., & Plunkett, W. K. (2022) · Leukemia · doi:10.1038/s41375-022-01553-w · Cited by 30

MCL-1 is a master regulator of cancer dependency on fatty acid oxidation

Prew, M. S., Adhikary, U., Choi, D. W., Portero, E. P., Paulo, J. A., Gowda, P., Budhraja, A., Opferman, J. T., Gygi, S. P., Danial, N. N., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111445 · Cited by 32

Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison

Chong, S. J. F., Lai, J. X. H., Eu, J. Q., Bellot, G. L., & Pervaiz, S. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7441 · Cited by 30

8-Chrysoeriol, as a potential BCL-2 inhibitor triggers apoptosis of SW1990 pancreatic cancer cells

Zhang, Y., Li, Z., Min, Q., Palida, A., Zhang, Y., Tang, R., Chen, L., & Li, H. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.01.042 · Cited by 30

Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy

Floros, K. V., Lochmann, T. L., Hu, B., Monterrubio, C., Hughes, M. T., Wells, J. D., Morales, C. B., Ghotra, M. S., Costa, C., Souers, A. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717820115 · Cited by 30

Targeting intrinsic cell death pathways to control fungal pathogens

Kulkarni, M., Stolp, Z. D., & Hardwick, J. M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.01.012 · Cited by 31

The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma

Buckarma, E. H., Werneburg, N. W., Conboy, C. B., Kabashima, A., O’Brien, D. R., Wang, C., Ilyas, S. I., & Smoot, R. L. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0165 · Cited by 30

Inhibition of glutathione metabolism attenuates esophageal cancer progression

Peng, L., Linghu, R., Chen, D., Yang, J., Kou, X., Wang, X.-Z., Hu, Y., Jiang, Y.-Z., & Yang, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.15 · Cited by 29

BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis

Heinicke, U., Haydn, T., Kehr, S., Vogler, M., & Fulda, S. (2018) · Oncogene · doi:10.1038/s41388-018-0212-5 · Cited by 29

The regulatory protein GADD34 inhibits TRAIL-induced apoptosis via TRAF6/ERK-dependent stabilization of myeloid cell leukemia 1 in liver cancer cells

Song, P., Yang, S., Hua, H. M., Zhang, H., Kong, Q., Wang, J., Luo, T. L., & Jiang, Y. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006029 · Cited by 29

BCL2 blockade overcomes MCL1 resistance in multiple myeloma

Siu, K. T., Huang, C., Panaroni, C., Mukaihara, K., Fulzele, K. S., Soucy, R., Reimonn, C. A., Cidado, J. R., Drew, L., Chattopadhyay, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0421-0 · Cited by 29

DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis

Milani, M., Beckett, A. J., Al-Zebeeby, A., Luo, X., Prior, I. A., Cohen, G. M., & Varadarajan, S. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0199-x · Cited by 32

Emerging approaches to target mitochondrial apoptosis in cancer cells

Gilmore, A. P., & King, L. (2019) · F1000Research · doi:10.12688/f1000research.18872.1 · Cited by 31

MUC1 Aptamer‐Capped Mesoporous Silica Nanoparticles for Navitoclax Resistance Overcoming in Triple‐Negative Breast Cancer

Vivo‐Llorca, G., Candela‐Noguera, V., Alfonso, M., García‐Fernández, A., Orzáez, M., Sancenón, F., & Martínez‐Máñez, R. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202001579 · Cited by 29

BH3 Mimetics in AML Therapy: Death and Beyond?

Cerella, C., Dicato, M. A., & Diederich, M. F. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.004 · Cited by 31

Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics

Koessinger, A. L., Cloix, C., Koessinger, D., Heiland, D. H., Bock, F. J., Strathdee, K. E., Kinch, K., Martínez‐Escardó, L., Paul, N. R., Nixon, C., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01001-3 · Cited by 30

Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies

Romanov‐Michailidis, F., Hsiao, C., Urner, L. M., Jerhaoui, S., Surkyn, M., Miller, B., Vos, A. M., Blanco, M. D., Bueters, R., Vinken, P., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01953 · Cited by 29

The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice

Brinkmann, K., Grabow, S., Hyland, C. D., Teh, C. E., Alexander, W. S., Herold, M. J., & Strasser, A. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.125 · Cited by 29

1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation

Xu, G., Liu, T., Zhou, Y., Yang, X., & Fang, H. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.08.024 · Cited by 29

MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma

(APGI), A. P. C. G. I., Castillo, L. E., Young, A. I. J., Mawson, A., Schafranek, P., Steinmann, A. M., Nessem, D., Parkin, A., Johns, A. L., Chou, A. S. Y., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1091-0 · Cited by 29

Photocatalytic proximity labelling of MCL-1 by a BH3 ligand

Beard, H. A., Hauser, J. R., Walko, M., George, R. M., Wilson, A. J., & Bon, R. S. (2019) · Communications Chemistry · doi:10.1038/s42004-019-0235-z · Cited by 29

BH3 Mimetics in Hematologic Malignancies

Klener, P., Sovilj, D., Renesova, N., & Andera, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810157 · Cited by 31

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Lasater, E. A., Amin, D. N., Bannerji, R., Mali, R. S., Barrett, K., Rys, R. N., Oeh, J., Lin, E., Sterne‐Weiler, T., Ingalla, E., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26809 · Cited by 31

MCL1 Can Be Targeted to Induce Apoptosis in Multiple Cancer Types

(2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2016-207

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

Maragno, A. L., Mistry, P., Kotschy, A., Szlavik, Z., Murray, J., Davidson, J. E. P., Toumelin-Braizat, G. L., Chanrion, M., Bruno, A., Clapéron, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4482 · Cited by 15

Development and Characterization of Novel Mcl-1 Inhibitors for Treatment of Cancer.

Mady, A. S. A. (2016) · Deep Blue (University of Michigan) · Cited by 1

Targeting MCL-1 in cancer: current status and perspectives

Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 318

Targeting MCL‐1 to Overcome Therapeutic Resistance and Improve Cancer Mortality

Mohiuddin, M. (2025) · Health Science Reports · doi:10.1002/hsr2.71390 · Cited by 9